Salofalk 1.5g Prolonged-Release Granules: SPC Overview
Quick summary Salofalk 1.5g prolonged-release granules contain mesalazine and are used for ulcerative colitis. This overview explains what the medicine is for, how it is taken, and the main safety points to check in...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary
Salofalk 1.5g prolonged-release granules contain mesalazine and are used for ulcerative colitis. This overview explains what the medicine is for, how it is taken, and the main safety points to check in the official leaflet or with a healthcare professional.
Medical disclaimer
This article is for general information only and is not a substitute for the official Summary of Product Characteristics (SPC), Patient Information Leaflet (PIL), or advice from a doctor or pharmacist. Do not use it to diagnose a condition or to change prescribed treatment.
What Salofalk 1.5g prolonged-release granules are used for
Salofalk 1.5g prolonged-release granules contain mesalazine. They are used in the treatment of ulcerative colitis, a long-term inflammatory bowel condition that affects the colon.
The original content describes use in mild to moderate ulcerative colitis, including treatment of active disease and helping maintain remission. If you are checking this medicine for a specific patient, the exact indication should always be confirmed in the official product information.
How Salofalk works
Mesalazine acts as an anti-inflammatory medicine in the intestinal lining. Salofalk is designed to release the active ingredient over time, helping it reach the affected area of the bowel.
According to the original content, this targeted action may help reduce inflammation and support healing of the damaged tissue in ulcerative colitis.
Key points from the original overview
- Contains mesalazine.
- Used for ulcerative colitis.
- Prolonged-release granules are designed for sustained delivery.
- Dosage depends on age, weight, and clinical situation.
- Monitoring may be needed, especially where kidney or liver concerns exist.
Dosage information
The original content states that dosage can vary depending on age and severity of disease. For adults, it mentions a typical starting range of 2 to 4 grams per day, taken as a single dose or in divided doses depending on tolerability.
For children over 6 years, the content notes that dosing is generally lower and may be based on body weight, with a commonly cited guide of 30 mg per kilogram per day, not exceeding the adult maximum dose.
Because dosing details can differ by product and patient, the official SPC and the prescriber’s instructions should always be checked before use.
| Topic | What the original content says |
|---|---|
| Active ingredient | Mesalazine |
| Main use | Ulcerative colitis |
| Formulation | Prolonged-release granules |
| Dose guidance | Varies by age, weight, and condition |
How it is taken
The original content says the granules should be mixed with water and taken immediately, following the instructions provided with the medicine. It also notes that the medicine may be taken before or after meals, but consistency in timing can be helpful.
If swallowing is difficult, the original article suggests speaking with a healthcare professional about suitable alternatives or formulations.
Possible side effects
The original content lists common gastrointestinal effects such as nausea, diarrhea, and abdominal discomfort. It also mentions that more serious reactions, although rare, can include hypersensitivity reactions, kidney issues, or liver function abnormalities.
Other symptoms mentioned in the source include fatigue, dizziness, rash, and itching. Any unusual or worsening symptoms should be discussed with a healthcare professional.
Monitoring and safety checks
The original article notes that people with pre-existing kidney or liver conditions may need regular monitoring. This is a general safety point from the source and should be confirmed in the official leaflet or by the prescriber.
What to check in the official leaflet
If you are reviewing Salofalk 1.5g prolonged-release granules, the official PIL or SPC should be checked for the most accurate and up-to-date details, including:
- exact indication and age range
- how to prepare and take the granules
- dose instructions for the specific patient group
- possible side effects and warning signs
- monitoring advice for kidney or liver function
Frequently asked questions
▸ How long does Salofalk granules take to work?
The original content says some people may notice improvement within a few days to a couple of weeks, while the full effect may take longer. Response can vary from person to person.
▸ Are Salofalk granules better than tablets?
The original content says the choice depends on patient preference and clinical circumstances. Both forms contain mesalazine, but the best option should be confirmed by a healthcare professional.
▸ What is mesalazine prolonged-release granules for?
According to the source, mesalazine prolonged-release granules are used mainly for ulcerative colitis to help reduce inflammation and support remission.
▸ What is the action of Salofalk granules?
The original content says Salofalk delivers mesalazine to the inflamed areas of the bowel, where it helps reduce inflammation and support healing.
▸ Where can I find the most accurate product details?
The official SPC and PIL are the best sources for exact dosing, warnings, and preparation instructions. A pharmacist can also help interpret the leaflet.
Safety reminder
Always follow the instructions on the prescription label and the official leaflet. If symptoms worsen, new side effects appear, or there are concerns about kidney or liver health, seek professional medical advice promptly.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
- Electronic Medicines Compendium (eMC) – Salofalk SPC/PIL
- NHS – Ulcerative colitis overview
- NICE – Ulcerative colitis guidance
- British National Formulary (BNF) – Mesalazine
To improve this article with specific references, add a custom field named _aio_sources in the post editor and write one source per line using: Source title|Source URL.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.